CDKN2A and malignant peripheral nerve sheath tumor: Future studies of the RABL6A-YAP link will reveal how biologically relevant this relationship is to MPNST genesis and whether co-targeting YAP with other RABL6A effectors, such as CDK-RB1 signaling, represents a valuable therapy regimen for Cdkn2a-altered MPNSTs.